Biotricity Inc. (BTCY): Price and Financial Metrics


Biotricity Inc. (BTCY): $1.11

-0.02 (-1.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BTCY Stock Price Chart Interactive Chart >

Price chart for BTCY

BTCY Price/Volume Stats

Current price $1.11 52-week high $5.30
Prev. close $1.13 52-week low $0.95
Day low $1.09 Volume 46,127
Day high $1.14 Avg. volume 132,087
50-day MA $1.30 Dividend yield N/A
200-day MA $2.45 Market Cap 56.92M

Biotricity Inc. (BTCY) Company Bio


Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It also involves in delivering, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology, is comprised of a monitoring device and software components, which is made available to the market, in order to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.


BTCY Latest News Stream


Event/Time News Detail
Loading, please wait...

BTCY Latest Social Stream


Loading social stream, please wait...

View Full BTCY Social Stream

Latest BTCY News From Around the Web

Below are the latest news stories about Biotricity Inc that investors may wish to consider to help them evaluate BTCY as an investment opportunity.

Biotricity Now Taking Pre-Orders for its Biotres Wireless Wearable Cardiac Monitoring Device

* Announcement follows FDA clearance * Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022REDWOOD CITY, CA / ACCESSWIRE / February 23, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company's three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias.

Yahoo | February 23, 2022

Maxim Group Sticks to Their Buy Rating for Biotricity (BTCY)

Maxim Group analyst Allen Klee reiterated a Buy rating on Biotricity (BTCY – Research Report) yesterday and set a price target of $7.00. The company's shares closed last Wednesday at $2.92. According to TipRanks.com, Klee is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.4% and a 21.9% success rate. Klee covers the Technology sector, focusing on stocks such as Advanced Human Imaging, Digital Turbine, and Mitek Systems. Currently, the analyst consensus on Biotricity is a Moderate Buy with an average price target of $6.50, an 116.7% upside from current levels. In a report released yesterday, H.C.

Christine Brown on TipRanks | February 17, 2022

Wall Street Analysts Are Bullish on Top Technology Picks

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Alteryx (AYX – Research Report) and Biotricity (BTCY – Research Report) with bullish sentiments. Alteryx (AYX) Rosenblatt Securities analyst Blair Abernethy maintained a Buy rating on Alteryx today and set a price target of $87.00. The company's shares closed last Tuesday at $52.19, close to its 52-week low of $49.67. According to TipRanks.

Howard Kim on TipRanks | February 16, 2022

BTCY: Topline Growth Continues Despite Omicron Headwinds as the Company Expands Salesforce & Is Unleashing New Revenue Streams Soon

By T. Moore, CFA NASDAQ:BTCY READ THE FULL BTCY RESEARCH REPORT Business News Update Biotricity Inc. (NASDAQ:BTCY) reported December quarter results of 93% sales growth from the year-ago quarter. 7% sequential sales growth was held back by Omicron COVID-19 causing the delay of patient visits and some temporary closings of clinics and doctor’s offices. Simply a deferral and pushout of revenues

Yahoo | February 16, 2022

Biotricity''s (BTCY) CEO Waqaas Al-Siddiq on Q3 2022 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 15, 2022

Read More 'BTCY' Stories Here

BTCY Price Returns

1-mo -15.91%
3-mo -9.76%
6-mo -58.27%
1-year -68.10%
3-year 79.06%
5-year -54.69%
YTD -72.11%
2021 439.08%
2020 17.17%
2019 31.27%
2018 -93.68%
2017 194.22%

Continue Researching BTCY

Want to see what other sources are saying about Biotricity Inc's financials and stock price? Try the links below:

Biotricity Inc (BTCY) Stock Price | Nasdaq
Biotricity Inc (BTCY) Stock Quote, History and News - Yahoo Finance
Biotricity Inc (BTCY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6207 seconds.